arrow
M

Mateus Crespo

The Institute of Cancer Research
H指数:41
被引数:5,776

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

IAP antagonist tolinapant (ASTX660) in combination with pembrolizumab in advanced solid tumors: a phase I trial

IAP拮抗剂托利那潘特(ASTX660)联合帕博利珠单抗治疗晚期实体瘤:一项I期临床试验

2026-09-300
OA
Corrigendum to “B7-H3 as a Therapeutic Target in Advanced Prostate Cancer” [European Urology 83 (2023) 224–238

勘误:“B7-H3 作为晚期前列腺癌的治疗靶点” [欧洲泌尿外科杂志 83 (2023) 224–238]

2026-08-070
OAAI
Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer

阐明靶向MCL1的分子分层单药及联合治疗策略,以治疗致命性前列腺癌

2025-10-080
OAAI
PERSEUS1: An Open-label, Investigator-initiated, Single arm, Phase 2 Trial Testing the Efficacy of Pembrolizumab in Patients with Metastatic Castration-resistant Prostate Cancer with Mismatch Repair Deficiency and Other Immune-sensitive Molecular Subtypes

PERSEUS1:一项开放标签、研究者发起的、单臂、II期临床试验,旨在评估帕博利珠单抗在错配修复缺陷型及其他免疫敏感分子亚型的转移性去势抵抗性前列腺癌患者中的疗效。

2025-06-010
OAAI
BCL2 expression is enriched in advanced prostate cancer with features of lineage plasticity
2024-09-170
OAAI
Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy

将STING激动剂靶向前列腺肿瘤的血管周围巨噬细胞可延迟对雄激素剥夺疗法的抵抗力

2024-07-252
OAAI
Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial

Capivasertib联合恩扎鲁他胺治疗多西他赛和阿比曲酮治疗转移性去势抵抗性前列腺癌: 随机II期RE-AKT试验的结果

2024-07-011
OAAI
RNASEH2B loss and PARP inhibition in advanced prostate cancer
2024-06-040
OAAI
Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer
2024-02-272
OAAI
Development and Validation of a New BAG-1L-Specific Antibody to Quantify BAG-1L Protein Expression in Advanced Prostate Cancer

一种新的BAG-1L-Specific抗体的开发和验证,以量化晚期前列腺癌中的BAG-1L蛋白表达

2023-11-011
OAAI
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance

靶向髓系趋化逆转前列腺癌治疗耐药

Nature
IF48.5
2023-10-160
OAAI
The Akt/mTOR and MNK/eIF4E pathways rewire the prostate cancer translatome to secrete HGF, SPP1 and BGN and recruit suppressive myeloid cells
2023-07-1712
OA
BCL2 expression is enriched in AR-independent advanced prostate cancer
2023-06-021
PRE
B7-H3 as a Therapeutic Target in Advanced Prostate Cancer (vol 83, pg 224, 2023)

B7-H3作为晚期前列腺癌的治疗靶点 (第83卷,224页,2023页)

2023-06-011
OA
Preliminary evidence of antitumor activity of Ipatasertib (Ipat) and Atezolizumab (A) in glioblastoma (GBM) patients (pts) with PTEN loss in the Phase 1 Ice-CAP trial (NCT03673787)
2023-04-142
PRE
Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer

转移性去势抵抗性前列腺癌的免疫标志物

2022-12-0114
PRE
Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors

guadecitabine (SGI-110) 联合pembrolizumab治疗实体瘤患者的1期剂量递增研究

2022-06-1826
OAAI
HER3 Is an Actionable Target in Advanced Prostate Cancer
2021-11-0931
OAAI